Non-invasive Current Stimulation for Restoration of Vision


The aim of the study is to evaluate effects of current stimulation of the brain on vision parameters, vision-related quality of life, and physiological parameters that allow concluding about the mechanisms of vision restoration. These include EEG-spectra and coherence measures, and visual evoked potentials. The design of stimulation protocols involves an appropriate sham-stimulation condition and sufficient follow-up periods to test whether the effects are stable. This is the first application of non-invasive current stimulation for vision rehabilitation in stroke-related visual field deficits.

Full Title of Study: “Non-invasive Current Stimulation for Restoration of Vision (REVIS) After Unilateral Occipital Stroke”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: December 31, 2019


  • Device: repetitive transorbital AC Stimulation
    • Repetitive transorbital ACS with max 30 Hz, 1,5 mA for 10 days, 20 min/day
  • Device: combination of transcranial direct current stimulaton and rtACS
    • Sequential tDCS (anodal occipital stimulation with 2 mA for 20 min/day for 10 days) and rtACS

Arms, Groups and Cohorts

  • Experimental: rtACS
    • repetitive transorbital ACS
  • Experimental: tDCS/rtACS
    • Sequential tDCS – tACS
  • Sham Comparator: Sham stimulation

Clinical Trial Outcome Measures

Primary Measures

  • Size of the visual field
    • Time Frame: 2 weeks
    • Mean threshold in standard static perimetry and and detection accuracy in HRP

Secondary Measures

  • Resting EEG power spectra
    • Time Frame: 2 weeks
    • EEG measurement using 128 channel

Participating in This Clinical Trial

Inclusion Criteria

  • HH due to ischemic or hemorrhagic stroke
  • age between 18 and 75 years
  • lesion age at least 6 months
  • stable visual field defect across baseline measurement (subjects with spontaneous fluctuations and recovery of vision excluded)
  • presence of residual vision and detectable gradual transition between the intact and the absolutely blind part of the visual field according to evaluation of the clinician
  • best corrected visual acuity at least 0.4 (20/50 Snellen) or better

Exclusion Criteria

  • known active malignancy
  • eye or central nervous system diseases that interfere with the study (including poorly controlled glaucoma)
  • electric or electronic implants (e.g. heart pacemaker)
  • metal artifacts in the eyes or head (with the exception of dental prosthesis or shunts)
  • expected low compliance (e.g. in case of known psychiatric disease, known drug abuse, and dementing syndromes)
  • epileptic seizure within the last 10 years
  • use of antiepileptic or sedative drugs

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Magdeburg
  • Collaborator
    • ERA-NET
  • Provider of Information About this Clinical Study
    • Principal Investigator: Bernhard A. Sabel, Prof. – University of Magdeburg

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.